SummaryBackgroundBoth French and international guidelines recommend long-term use of betablockers, antiplatelet drugs, statins, angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers (ACE-I/ARB) after a myocardial infarction (MI), but data on their combined use are scarce in France.AimsTo evaluate the use of combined medication 6months after hospital admission for MI and the factors that can significantly influence their use.MethodsAll hospital admissions for MI in France from January to June 2006 were selected from the national hospital discharge database. Data on medications used 6months before and after hospitalization for patients covered by the general health insurance scheme (70% of French population) were collected...
Acute coronary syndrome (ACS) causes approximately 100,000 hospitalisations per year in France. In s...
Acute coronary syndrome (ACS) causes approximately 100,000 hospitalisations per year in France. In s...
Acute coronary syndrome (ACS) causes approximately 100,000 hospitalisations per year in France. In s...
SummaryBackgroundBoth French and international guidelines recommend long-term use of betablockers, a...
Myocardial infarction is a major cause of morbidity and mortality. Guidelines have been published to...
Aim. Primary aim was to determine the percentage of myocardial infarction patients using guideline-r...
BACKGROUND: After myocardial infarction, guidelines recommend pharmaceutical treatment with a combin...
Objective: To determine the percentage of myocardial infarction patients in the Netherlands still us...
Objective: To determine the percentage of myocardial infarction patients in the Netherlands still us...
Background: Guidelines for cardiovascular secondary prevention are based on evidence from relatively...
International audienceMyocardial infarction is a major cause of morbidity and mortality. Guidelines ...
Background: Guidelines for cardiovascular secondary prevention are based on evidence from relatively...
Background: Guidelines for cardiovascular secondary prevention are based on evidence from relatively...
Background: Guidelines for cardiovascular secondary prevention are based on evidence from relatively...
BackgroundThe French guidelines recommend dual antiplatelet therapy after acute myocardial infarctio...
Acute coronary syndrome (ACS) causes approximately 100,000 hospitalisations per year in France. In s...
Acute coronary syndrome (ACS) causes approximately 100,000 hospitalisations per year in France. In s...
Acute coronary syndrome (ACS) causes approximately 100,000 hospitalisations per year in France. In s...
SummaryBackgroundBoth French and international guidelines recommend long-term use of betablockers, a...
Myocardial infarction is a major cause of morbidity and mortality. Guidelines have been published to...
Aim. Primary aim was to determine the percentage of myocardial infarction patients using guideline-r...
BACKGROUND: After myocardial infarction, guidelines recommend pharmaceutical treatment with a combin...
Objective: To determine the percentage of myocardial infarction patients in the Netherlands still us...
Objective: To determine the percentage of myocardial infarction patients in the Netherlands still us...
Background: Guidelines for cardiovascular secondary prevention are based on evidence from relatively...
International audienceMyocardial infarction is a major cause of morbidity and mortality. Guidelines ...
Background: Guidelines for cardiovascular secondary prevention are based on evidence from relatively...
Background: Guidelines for cardiovascular secondary prevention are based on evidence from relatively...
Background: Guidelines for cardiovascular secondary prevention are based on evidence from relatively...
BackgroundThe French guidelines recommend dual antiplatelet therapy after acute myocardial infarctio...
Acute coronary syndrome (ACS) causes approximately 100,000 hospitalisations per year in France. In s...
Acute coronary syndrome (ACS) causes approximately 100,000 hospitalisations per year in France. In s...
Acute coronary syndrome (ACS) causes approximately 100,000 hospitalisations per year in France. In s...